Untitled

Abstract

Background and RationaleAutologous, meaning self, blood derivate products have been used to treat several ocular surface pathologic conditions for more than four decades now. They were first mentioned in ophthalmologic-related literature in 1975, when a mobile ocular perfusion pump containing a patient's autologous serum was used to treat conditions such as Stevens-Johnson Syndrome (SJS), ocular pemphigoid, Keratoconjunctivitis Sicca (KCS), chemical burns, and Persistent Epithelial Defects (PED),